Metastatic Castration-Resistant Prostate Cancer (mCRPC)
CELCCelcuityCatalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for Gedatolisib + darolutamide (Nubeqa®) in Metastatic Castration-Resistant Prostate Cancer (mCRPC). The expected timing is based on the latest available company guidance and may change.
05/14/26:- PR No update. 08/13/26:- Ph1b 240 mg evaluation completed; 300 mg evaluation is ongoing. Updated data and strategy will be provided in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.